3.82

3.54% -0.14

Sab Biotherapeutics Inc (SABS)

Overview News Price History Financials Discussions Forecast

Sab Biotherapeutics Inc stock is traded at $3.82, with a volume of 296.38K. It is down -3.54% in the last 24 hours and up +15.41% over the past month. SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Previous Close:

$3.96

Open:

$3.96

24h Volume:

296.38K

Relative Volume:

0.35

Market Cap:

$292.09M

Revenue:

$114.70K

Net Income/Loss:

$-26.49M

P/E Ratio:

-1.5488

EPS:

-2.4665

Net Cash Flow:

$-53.17M

1W Performance:

-2.55%

1M Performance:

+15.41%

6M Performance:

+3.80%

1Y Performance:

+52.79%

1-Day Range:

$3.72

$3.96

1-Week Range:

$3.54

$4.07

52-Week Range:

$1.85

$6.60

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name

Sab Biotherapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

305-845-2813

Address

777 W 41ST ST, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

SABS's Discussions on Twitter

Compare SABS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SABS Sab Biotherapeutics Inc	3.82	292.09M	114.70K	-26.49M	-53.17M	-2.4665
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-02-26	Initiated	Rodman & Renshaw	Buy
Dec-19-25	Initiated	Guggenheim	Buy
Sep-17-25	Initiated	Leerink Partners	Outperform
May-14-25	Resumed	H.C. Wainwright	Buy
Oct-09-24	Initiated	Craig Hallum	Buy
Aug-28-24	Initiated	Oppenheimer	Outperform
Nov-05-21	Initiated	Chardan Capital Markets	Buy

View All

Sab Biotherapeutics Inc Stock (SABS) Latest News

Jul 07, 2026

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks

Jul 07, 2026

Breakthrough T1D Awards Grant for SAB-142 PRISE-hATG Study to Advance Type 1 Diabetes Therapies Beyond 100 Days Post-Diagnosis – Minichart - Minichart

Jul 07, 2026

Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView

Jul 07, 2026

Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan

Jul 07, 2026

Breakthrough T1D backs SAB-142 study beyond the first 100 days - Stock Titan

Jul 07, 2026

Jul 05, 2026

Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co

Jul 05, 2026

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance

Jul 05, 2026

Jul 03, 2026

SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView

Jul 03, 2026

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView

Jul 03, 2026

Jul 01, 2026

SABSW Plunges to Penny Level as Biotech Warrant Faces Continued Selling PressureSupport Level Bounce - dars.gov.et

Jul 01, 2026

Jun 30, 2026

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Small Cap Completeness Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView

Jun 27, 2026

Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView

Jun 27, 2026

Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com - Investing.com South Africa

Jun 27, 2026

Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView

Jun 27, 2026

Jun 26, 2026

SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jun 2026 $SABS - MarketBeat

Jun 25, 2026

Jun 24, 2026

Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com - Investing.com South Africa

Jun 24, 2026

Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target - marketscreener.com

Jun 24, 2026

Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com

Jun 24, 2026

Jun 23, 2026